Alzchem Group AG

Latest Results (25.07.2026):

Alzchem Group AG – Q1 2026: Alzchem posted a positive start to 2026 with consolidated sales of EUR 148.7 million (‑ up 3% year‑over‑year) and consolidated EBITDA of EUR 32.3 million (‑ up 18%), lifting the EBITDA margin to 21.7% (Q1 2025: 18.9%). Earnings per share rose to EUR 1.77. The Specialty Chemicals segment drove the improvement while Basics & Intermediates declined as expected; the company confirms its full‑year 2026 guidance and expects stronger growth momentum in H2 2026.

Financial headline

Q1 2026 sales: EUR 148,653k (+3% vs Q1 2025). EBITDA: EUR 32,286k (+18%). EBITDA margin: 21.7% (vs 18.9%). Consolidated result: EUR 18,001k (+23%). EPS: EUR 1.77 (based on 10,123,706 shares).

Segment performance

Specialty Chemicals: sales EUR 105,298k (+11%), EBITDA EUR 31,484k (margin 29.9%). Basics & Intermediates: sales EUR 36,666k (‑14%), EBITDA EUR 284k (margin 0.8%) — volume and pricing pressure in agri/pharma. Other & Holding: lower revenue and slightly reduced EBITDA vs prior year.

Cash flow & balance sheet

Operating cash flow Q1: EUR 37,667k. Investing cash outflow: EUR 36,565k. Free cash flow: EUR 1,102k. Cash and cash equivalents: EUR 69,347k. Total assets: EUR 654,476k (up EUR 36,797k vs 12/31/2025). Equity: EUR 276,062k; equity ratio: 42.2%. Positive net cash after bank liabilities: ~EUR 29,841k.

Customer subsidies & accounting impact

Q1 2026 customer prepayments received: EUR 5,973k (vs EUR 39,501k in Q1 2025). Non‑current contract liabilities (related to nitroguanidine capacity subsidies) EUR 89,484k and current contract liabilities EUR 3,668k as of 31/03/2026. Related receivables from future customer payments: non‑current EUR 17,698k, current EUR 10,468k. These items increase operating cash flow when received and expand the balance sheet; revenue recognition will follow IFRS 15 upon delivery from the new capacities and had no material income‑statement impact in Q1.

Operational updates

Carbide furnace renovation on schedule and within budget; recommissioning expected early July 2026 (inventories were built to cover shutdown). Expansion of guanidine nitrate/nitroguanidine capacity in Germany progressing to deliver additional volumes in H2 2026; U.S. site search underway for an additional nitroguanidine facility (target completion by end‑2029). Creatine investment program (~EUR 120m) advancing; phased commissioning from H2 2027.

Outlook

FY 2026 guidance confirmed: consolidated sales growing toward ~EUR 600m, adjusted EBITDA toward ~EUR 126m, adjusted EBITDA margin ~21% (company expects acceleration in H2 2026). Management flags risks from supply‑chain disruptions, raw‑material/transport cost inflation and competitive pricing in some markets; planned price adjustments to pass on increased input costs.

Shareholder & misc. items

Free float increased to nearly 75%. Financing cash outflow in Q1 included scheduled debt repayments and payments related to the share‑buyback execution. No significant post‑balance‑sheet events reported. Summarized from source with an LLMView Source